Boehringer Ingelheim Pharma GmbH & Co KG and CDR-Life Inc. have entered into a new global licensing agreement to develop CDR-111 for autoimmune diseases.
CDR-609 is a T-cell engager therapeutic from CDR-Life Inc. that targets Leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5) with potential for treating colorectal cancer.
CDR-Life Inc. has announced CDR-609 as its next clinical candidate. Built on the company’s proprietary M-gager platform, CDR-609 is a novel T-cell engager targeting LGR5, a surface antigen widely expressed on common solid tumors, including colorectal, gastric, liver and pancreatic cancers.
CDR-Life Inc. has reported preclinical data for the CDR-813, a novel antibody fragment-based bivalent T-cell engager targeting preferentially expressed antigen in melanoma (PRAME) on HLA-A*02:01.
CDR-Life Inc. has expanded its pipeline of novel T-cell engagers (TCE) with the addition of CDR-813 and CDR-505. CDR-813 is a highly potent and selective TCE candidate targeting tumors expressing PRAME (preferentially expressed antigen in melanoma) in HLA-A*02:01 patients.
CDR-Life Inc. has announced FDA clearance of an IND application for CDR-404, its lead program in development as a precision immunotherapy for solid tumors.
CDR-Life Inc. has closed a $76 million series A round to advance development of a new generation of cancer immunotherapies designed to treat solid tumors by targeting intracellular antigens that occur only in tumors, with the aim of increasing effectiveness while reducing off-target effects.
